文献速递核素与放射性配体治疗肿瘤 PET/CT

放射性配体治疗中肿瘤响应的建模与预测

Modeling and Predicting Tumor Response in Radioligand Therapy.
PubMed 文献 · J Nucl Med · 2018-05-10

本研究基于治疗前PET/CT测量和生理药代动力学/药效学(PBPK/PD)模型,以177Lu标记的PSMA I&T为例,回顾性分析13例转移性去势抵抗性前列腺癌患者,预测放射性配体治疗后PSMA阳性肿瘤体积。治疗后6周预测与实测肿瘤体积的相对偏差为1%±40%(排除1例PSA阴性患者),PSA阳性患者放射敏感性为0.0172±0.0084 Gy⁻¹。作者认为该方法是首次仅用PET/CT和建模预测RLT后肿瘤体积的尝试,内部验证显示可行且精度可接受,方法改进与外部验证正在进行中。

要点

  • 基于治疗前PET/CT和PBPK/PD建模预测177Lu-PSMA I&T RLT后6周PSMA阳性肿瘤体积。
  • 13例mCRPC患者回顾性分析,预测与实测肿瘤体积相对偏差1%±40%(排除1例PSA阴性患者)。
  • PSA阳性患者放射敏感性为0.0172±0.0084 Gy⁻¹,内部Jackknife验证显示可行且精度可接受。

核心结论

  • 据作者所知,所提方法是首次仅使用PET/CT和建模方法预测RLT后PSMA阳性肿瘤体积的尝试。
  • 内部验证显示该方法可行且精度可接受,方法的改进和模型的外部验证正在进行中。

研究设计与样本

  • 回顾性分析13例转移性去势抵抗性前列腺癌患者的数据。
  • 将新近开发的177Lu-PSMA I&T RLT的PBPK模型扩展以纳入肿瘤指数生长和照射所致减少(线性二次模型)。
  • 在贝叶斯框架中同时拟合药代动力学/药效学参数至PET/CT活度浓度、平面闪烁显像数据及治疗前和治疗后6周的肿瘤体积。
  • 采用留一法Jackknife方法进行验证。
  • 基于治疗前PET/CT成像和PBPK/PD建模预测治疗后肿瘤体积。

主要发现

  • 排除1例前列腺特异性抗原阴性患者后,PSMA阳性肿瘤细胞治疗后6周预测与实测肿瘤体积的相对偏差为1%±40%。
  • PSA阳性患者的放射敏感性确定为0.0172±0.0084 Gy⁻¹。

局限性

  • 原文报告内部验证显示该方法可行且精度可接受,方法改进和模型外部验证正在进行中。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The aim of this work was to develop a theranostic method that allows prediction of prostate-specific membrane antigen (PSMA)-positive tumor volume after radioligand therapy (RLT) based on a pretherapeutic PET/CT measurement and physiologically based pharmacokinetic/pharmacodynamic (PBPK/PD) modeling at the example of RLT using 177Lu-labeled PSMA for imaging and therapy (PSMA I&T). Methods: A recently developed PBPK model for 177Lu-PSMA I&T RLT was extended to account for tumor (exponential) growth and reduction due to irradiation (linear quadratic model). Data from 13 patients with metastatic castration-resistant prostate cancer were retrospectively analyzed. Pharmacokinetic/pharmacodynamic parameters were simultaneously fitted in a Bayesian framework to PET/CT activity concentrations, planar scintigraphy data, and tumor volumes before and after (6 wk) therapy. The method was validated using the leave-one-out Jackknife method. The tumor volume after therapy was predicted on the basis of pretherapy PET/CT imaging and PBPK/PD modeling. Results: The relative deviation of the predicted and measured tumor volume for PSMA-positive tumor cells (6 wk after therapy) was 1% ± 40%, excluding 1 patient (prostate-specific antigen-negative) from the population. The radiosensitivity for the prostate-specific antigen-positive patients was determined to be 0.0172 ± 0.0084 Gy-1Conclusion: To our knowledge, the proposed method is the first attempt to solely use PET/CT and modeling methods to predict the PSMA-positive tumor volume after RLT. Internal validation shows that this is feasible with an acceptable accuracy. Improvement of the method and external validation of the model is ongoing.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Kletting P, Thieme A, Eberhardt N, et al. Modeling and Predicting Tumor Response in Radioligand Therapy. J Nucl Med. 2018. PMID: 29748236. doi:10.2967/jnumed.118.210377

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。